Beyond Angiotensin-Converting Enzyme Inhibitors : Modulation of the Renin–Angiotensin–Aldosterone System to Delay or Manage Congestive Heart Failure - 03/10/23
, Darcy B. Adin, DVM, DACVIM (Cardiology) b, James Wood, DVM aRésumé |
The renin–angiotensin–aldosterone system (RAAS) consists of bioactive angiotensin peptides, enzymatic pathways, receptors, and the steroid hormone aldosterone. The RAAS regulates blood pressure, sodium, and electrolyte homeostasis and mediates pathologic disease processes. Within this system is an alternative arm that counterbalances the vasoconstrictive, sodium and water retentive, and pro-fibrotic and inflammatory effects of the classical arm. Improved biochemical methodologies in RAAS quantification are elucidating how this complex system changes in health and disease. Future treatments for cardiovascular and kidney disease will likely involve a more nuanced manipulation of this system rather than simple blockade.
Le texte complet de cet article est disponible en PDF.Keywords : Diuretics, Angiotensin 1,7, Angiotensin-converting enzyme 2, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Mineralocorticoid receptor antagonist
Plan
Vol 53 - N° 6
P. 1353-1366 - novembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
